Axial Spondyloarthritis (axSpA) - Pipeline Insight - 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Axial Spondyloarthritis – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial Spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Axial Spondyloarthritis: Overview
Axial Spondyloarthritis (Axial SpA) is a chronic, immune-mediated inflammatory condition characterised by inflammation of the sacroiliac joints (sacroiliitis), inflammation of the spine or both resulting in chronic back pain, fatigue and significantly reduced function and quality of life. It is an umbrella term for the types of inflammatory arthritis that primarily affect the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis. Axial SpA may be categorized as either radiographic axial spondyloarthritis (r-axSpA) (also known as Ankylosing Spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) depending on the presence of radiographic sacroiliitis.
Symptoms
The primary symptom of Axial Spondyloarthritis (Axial SpA) is back pain that occurs because of chronic inflammation in the joints of spine. Other symptoms of Axial Spondyloarthritis include:
Axial SpA is often mis-diagnosed or not diagnosed for several years after a patient first experiences symptoms. Early diagnosis is essential for optimal patient care. A diagnosis of Axial Spondyloarthritis is done thorough a combination of patient history, physical examination, and blood tests (both for HLA-B27 and for markers of inflammation, such as C-reactive protein), and imaging tests, such as X-ray and MRI.
Treatment
Treatment for Axial Spondyloarthritis includes, NSAIDs, Biologics that are either tumor necrosis factor (TNF) inhibitor or an anti-IL-17 agent, Sulfasalazine, Analgesics, and Glucocorticoids (corticosteroids). Some of the approved biologics and their biosimilars are adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade) and secukinumab (Cosentyx). Physiotherapy as a treatment for axial SpA aims to maintain or improve function.
Axial Spondyloarthritis Emerging Drugs Chapters
This segment of the Axial Spondyloarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Axial Spondyloarthritis Emerging Drugs
Further product details are provided in the report
Axial Spondyloarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Axial Spondyloarthritis drugs segregated based on following parameters that define the scope of the report, such as:
Axial Spondyloarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial Spondyloarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial Spondyloarthritis drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Axial Spondyloarthritis – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial Spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Axial Spondyloarthritis: Overview
Axial Spondyloarthritis (Axial SpA) is a chronic, immune-mediated inflammatory condition characterised by inflammation of the sacroiliac joints (sacroiliitis), inflammation of the spine or both resulting in chronic back pain, fatigue and significantly reduced function and quality of life. It is an umbrella term for the types of inflammatory arthritis that primarily affect the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis. Axial SpA may be categorized as either radiographic axial spondyloarthritis (r-axSpA) (also known as Ankylosing Spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) depending on the presence of radiographic sacroiliitis.
Symptoms
The primary symptom of Axial Spondyloarthritis (Axial SpA) is back pain that occurs because of chronic inflammation in the joints of spine. Other symptoms of Axial Spondyloarthritis include:
- nocturnal waking caused by pain
- morning stiffness
- fatigue and functional disability
- Inflammation of the eye (uveitis)
- Psoriasis
- Inflammatory bowel disease
- Enthesitis
Axial SpA is often mis-diagnosed or not diagnosed for several years after a patient first experiences symptoms. Early diagnosis is essential for optimal patient care. A diagnosis of Axial Spondyloarthritis is done thorough a combination of patient history, physical examination, and blood tests (both for HLA-B27 and for markers of inflammation, such as C-reactive protein), and imaging tests, such as X-ray and MRI.
Treatment
Treatment for Axial Spondyloarthritis includes, NSAIDs, Biologics that are either tumor necrosis factor (TNF) inhibitor or an anti-IL-17 agent, Sulfasalazine, Analgesics, and Glucocorticoids (corticosteroids). Some of the approved biologics and their biosimilars are adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade) and secukinumab (Cosentyx). Physiotherapy as a treatment for axial SpA aims to maintain or improve function.
Axial Spondyloarthritis Emerging Drugs Chapters
This segment of the Axial Spondyloarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Axial Spondyloarthritis Emerging Drugs
- Namilumab: Izana Bioscience Ltd.
- Bimekizumab: UCB
Further product details are provided in the report
Axial Spondyloarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Axial Spondyloarthritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Axial Spondyloarthritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Axial Spondyloarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial Spondyloarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial Spondyloarthritis drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Axial Spondyloarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Axial Spondyloarthritis.
- Axial Spondyloarthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Axial Spondyloarthritis drugs?
- How many Axial Spondyloarthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axial Spondyloarthritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axial Spondyloarthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Axial Spondyloarthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Izana Bioscience
- Kyowa Kirin Co. Ltd.
- Luye Pharma Group
- UCB
- Galapagos
- Gilead Sciences
- Almirall
- Sun Pharmaceutical Industries
- AbbVie
- Pfizer
- Akeso Biopharma
- Nimbus Therapeutics
- Eisai Inc.
- Roivant Sciences
- Jiangsu Hengrui Medicine Co.
- Namilumab
- KHK4827
- Secukinumab biosimilar
- Bimekizumab
- Filgotinib
- Upadacitinib
- Tofacitinib
- Tildrakizumab
- AK-111
- NDI 031232
- Gimsilumab
- QX002N Qyuns Therapeutics
- SHR-0302
Introduction
Executive Summary
Axial Spondyloarthritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Axial Spondyloarthritis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Axial Spondyloarthritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Axial Spondyloarthritis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Bimekizumab - UCB
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Namilumab: Izana Bioscience Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
QX002N: Qyuns Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
AK-111: Akeso Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Axial Spondyloarthritis Key Companies
Axial Spondyloarthritis Key Products
Axial Spondyloarthritis- Unmet Needs
Axial Spondyloarthritis- Market Drivers and Barriers
Axial Spondyloarthritis- Future Perspectives and Conclusion
Axial Spondyloarthritis Analyst Views
Axial Spondyloarthritis Key Companies
Appendix
Executive Summary
Axial Spondyloarthritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Axial Spondyloarthritis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Axial Spondyloarthritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Axial Spondyloarthritis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Bimekizumab - UCB
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Namilumab: Izana Bioscience Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
QX002N: Qyuns Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
AK-111: Akeso Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Axial Spondyloarthritis Key Companies
Axial Spondyloarthritis Key Products
Axial Spondyloarthritis- Unmet Needs
Axial Spondyloarthritis- Market Drivers and Barriers
Axial Spondyloarthritis- Future Perspectives and Conclusion
Axial Spondyloarthritis Analyst Views
Axial Spondyloarthritis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Axial Spondyloarthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Axial Spondyloarthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Axial Spondyloarthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Axial Spondyloarthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
